{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:57:34Z","timestamp":1780981054422,"version":"3.54.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Twice-daily dosing of Dolutegravir is approved for adults with HIV and integrase strand transfer inhibitor resistance, but not for children. Population pharmacokinetic modeling and simulations identified a weight-tiered twice-daily dose for children, predicted to yield dolutegravir exposures within the therapeutic window and provide similar efficacy and safety as seen in adults with HIV-1 and first-generation integrase strand transfer inhibitor resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005158","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:00:45Z","timestamp":1770181245000},"page":"620-622","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance"],"prefix":"10.1097","volume":"45","author":[{"given":"Hardik","family":"Chandasana","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Modeling Simulation, GSK, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Buchanan","sequence":"additional","affiliation":[{"name":"Clinical Medical Development Pediatrics, ViiV Healthcare, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy E.","family":"Henegar","sequence":"additional","affiliation":[{"name":"Epidemiology and Real-World Evidence, ViiV Healthcare, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McKenna","sequence":"additional","affiliation":[{"name":"Safety Evaluation And Risk Management, GSK, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Vavro","sequence":"additional","affiliation":[{"name":"Clinical Development Pediatrics, ViiV Healthcare, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Puga","sequence":"additional","affiliation":[{"name":"Global Medical Lead Pediatrics, ViiV Healthcare, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Brothers","sequence":"additional","affiliation":[{"name":"Scientific Medical Office, ViiV Healthcare, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Tan","sequence":"additional","affiliation":[{"name":"Clinical Medical Development, ViiV Healthcare Ltd, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bush","sequence":"additional","affiliation":[{"name":"Global Clinical Pharmacology, ViiV Healthcare, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4444-1950","authenticated-orcid":false,"given":"Rashmi","family":"Mehta","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling Simulation, GSK, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Paul","sequence":"additional","affiliation":[{"name":"Pediatrics-Retrovirology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Lewis","sequence":"additional","affiliation":[{"name":"Clinical and Regulatory Affairs, The Clinton Health Access Initiative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Ruel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"R2-20260609","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor.","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-20260609","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/QAD.0b013e32834a1dd9","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.","volume":"25","author":"Min","year":"2011","journal-title":"AIDS"},{"key":"R4-20260609","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jcph.2494","article-title":"Population pharmacokinetic analysis of dolutegravir in treatment-experienced adults living with HIV-1.","volume":"64","author":"Chandasana","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"R6-20260609","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40262-023-01289-5","article-title":"Population pharmacokinetic modeling of dolutegravir to optimize pediatric dosing in HIV-1-infected infants, children, and adolescents.","volume":"62","author":"Chandasana","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R7-20260609","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"R8-20260609","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jcph.744","article-title":"Exposure matching for extrapolation of efficacy in pediatric drug development.","volume":"56","author":"Mulugeta","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"R9-20260609","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"R10-20260609","doi-asserted-by":"crossref","first-page":"1","DOI":"10.37796\/2211-8039.1422","article-title":"Mutation patterns of integrase gene affect antiretroviral resistance in various non-B subtypes of human immunodeficiency virus type-1 and their implications for patients\u2019 therapy.","volume":"13","author":"Djojosugito","year":"2023","journal-title":"Biomedicine (Taipei)"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:01:21Z","timestamp":1780977681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005158","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]}}}